KR20190126314A - 암-선택적 표지화 및 표적화를 위한 트리거 활성화 가능한 당 접합체 - Google Patents

암-선택적 표지화 및 표적화를 위한 트리거 활성화 가능한 당 접합체 Download PDF

Info

Publication number
KR20190126314A
KR20190126314A KR1020197025795A KR20197025795A KR20190126314A KR 20190126314 A KR20190126314 A KR 20190126314A KR 1020197025795 A KR1020197025795 A KR 1020197025795A KR 20197025795 A KR20197025795 A KR 20197025795A KR 20190126314 A KR20190126314 A KR 20190126314A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
moiety
group
trigger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197025795A
Other languages
English (en)
Korean (ko)
Inventor
지안준 청
카이민 카이
진 유
Original Assignee
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Publication of KR20190126314A publication Critical patent/KR20190126314A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197025795A 2017-02-10 2018-02-12 암-선택적 표지화 및 표적화를 위한 트리거 활성화 가능한 당 접합체 Withdrawn KR20190126314A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457597P 2017-02-10 2017-02-10
US62/457,597 2017-02-10
PCT/US2018/017802 WO2018148650A1 (en) 2017-02-10 2018-02-12 Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Publications (1)

Publication Number Publication Date
KR20190126314A true KR20190126314A (ko) 2019-11-11

Family

ID=63107851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025795A Withdrawn KR20190126314A (ko) 2017-02-10 2018-02-12 암-선택적 표지화 및 표적화를 위한 트리거 활성화 가능한 당 접합체

Country Status (6)

Country Link
US (1) US11299509B2 (https=)
EP (1) EP3595729A4 (https=)
JP (1) JP2020507584A (https=)
KR (1) KR20190126314A (https=)
CN (1) CN110520161A (https=)
WO (1) WO2018148650A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
WO2020061129A1 (en) * 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US20220251126A1 (en) * 2019-08-05 2022-08-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticancer agents
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
WO2021155297A1 (en) * 2020-01-29 2021-08-05 President And Fellows Of Harvard College Methods for labeling and targeting cells
CA3198230A1 (en) * 2021-01-28 2022-08-04 Jian Chen Conjugate and use thereof
MX2024005637A (es) * 2021-11-08 2024-07-29 Shanghai Best Link Bioscience Llc Un conjugado de fármaco basado en e-poli-l-lisina, sus intermediarios y aplicaciones.
CN120380004A (zh) * 2022-12-08 2025-07-25 杭州瑞奥生物医药有限公司 单糖、药物组合物及诊断和治疗应用
CN116239640B (zh) * 2023-01-19 2024-03-08 中国药科大学 吉西他滨前药及其医药用途
CN116655715B (zh) * 2023-07-27 2023-10-20 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途
CN121889407A (zh) * 2023-08-15 2026-04-17 杭州瑞奥生物医药有限公司 可被aldh活化的功能化单糖、药物组合物及诊断和治疗应用
CN118603851A (zh) * 2024-05-22 2024-09-06 杭州瑞奥生物医药有限公司 一种检测细胞表面叠氮的两步法荧光标记流式方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630351B1 (en) * 1999-06-07 2003-10-07 Mirus Corporation Compositions and methods for drug delivery using pH sensitive molecules
DK3248613T3 (da) * 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
US9321796B2 (en) 2012-06-28 2016-04-26 Universiteit Gent Galactopyranosyl derivatives useful as medicaments
CN105142672B (zh) * 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
US9943624B2 (en) 2012-11-30 2018-04-17 University Of Massachusetts Multi-functional surface coating of implants
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9695189B2 (en) * 2013-03-01 2017-07-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015021305A1 (en) 2013-08-09 2015-02-12 The Research Foundation For The State Univeristy Of New York Cancer cell specific imaging probes and methods of use
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
PT3250237T (pt) * 2015-01-30 2021-06-30 Sutro Biopharma Inc Derivados de hemiasterlina para conjugação e terapêutica
KR20180058737A (ko) 2015-10-07 2018-06-01 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Also Published As

Publication number Publication date
EP3595729A1 (en) 2020-01-22
CN110520161A (zh) 2019-11-29
US20190367550A1 (en) 2019-12-05
JP2020507584A (ja) 2020-03-12
WO2018148650A1 (en) 2018-08-16
EP3595729A4 (en) 2022-01-12
US11299509B2 (en) 2022-04-12

Similar Documents

Publication Publication Date Title
KR20190126314A (ko) 암-선택적 표지화 및 표적화를 위한 트리거 활성화 가능한 당 접합체
JP6892694B2 (ja) 癌選択性標識化及び標的指向化のためのトリガー活性型代謝糖前駆体
US10905762B2 (en) Targeted nanoparticle conjugates
JP6932389B2 (ja) 標的化コンジュゲートならびにその粒子及び製剤
CA2799773C (fr) Nouveaux bras autoreactifs et prodrogues les comprenant
CN106573073A (zh) Fap激活的治疗剂以及其相关用途
JP6543342B2 (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
JP2017506628A (ja) がん及び炎症性疾患の治療のための結合体及びプロドラッグ
CN109922834B (zh) 用于治疗癌症的卟啉化合物和组合物
JP2019515025A (ja) トポイソメラーゼ毒
KR102346268B1 (ko) 경구 항암 전구약물을 포함하는 복합체, 이의 제조방법 및 이의 용도
JP7620569B2 (ja) がん治療のための新規治療用ベクター及びプロドラッグ
CN101410139A (zh) 施陶丁格连接在生物活性化合物的体内组装中的用途
KR20250174687A (ko) 세포독성제를 전달하기 위한 항체-약물 접합체
KR20260028651A (ko) 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN106344930A (zh) 分子定点靶向和激活的短肽阿霉素的制备和用途
CN118076388A (zh) 靶向β-D-N-乙酰氨基葡萄糖苷酶的载体
Wang et al. A Dual-mechanism Targeted Cross-convergence Prodrug Activation Strategy Enabled by Biological Stimulus Amplification towards Precision Cancer Therapy
HK40008068A (en) Porphyrin compounds and compositions useful for treating cancer
HK40008068B (zh) 用於治疗癌症的卟啉化合物和组合物
HK1236815A1 (en) Conjugates and prodrugs for treating of cancer and inflammatory diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190902

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210209

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210408

WITB Written withdrawal of application